quotient sciences clinical content

  1. Open-Label Study Assessing Relative And Absolute Bioavailability 1/26/2026

    Consistent absorption across different formulations and dietary conditions ensures stable therapeutic exposure. This flexibility simplifies patient dosing schedules and supports manufacturing transitions.

  2. Fast-Track Innovation, Address CMC Challenges In Expedited Pathways 1/26/2026

    Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.

  3. Fast-Tracking FIH To PoC: Strategies For Accelerated Drug Development 1/12/2026

    Three factors often decide success or failure in FIH studies: integrating biomarkers and pharmacodynamic endpoints, including patients in the trials, and leveraging purpose-built manufacturing infrastructure.

  4. De-Risking FIH: Integrated Strategies For Rapid Proof-Of-Concept 12/17/2025

    Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept.

  5. How To Capture Growth In The Expanding Metabolic Drug Market 12/2/2025

    Driven by GLP-1 success and rising obesity rates, R&D investment in metabolic disease therapies now rivals oncology, demanding rapid development to overcome market challenges.

  6. Translational Pharmaceutics® For First-In-Human Studies 10/16/2025

    Re-engineer your drug's path into clinical development and accelerate time to Proof-of-Concept. Real-time data guides rapid formulation iterations, minimizing drug substance use and lowering program risk.

  7. Human ADME Studies: Human Metabolism Data For Regulatory Submission 10/16/2025

    Integrated human ADME studies streamline the process from 14C synthesis to clinical conduct and final reporting to accelerate your drug development program.

  8. High Potency Handling Capabilities And Support 10/15/2025

    Highly potent APIs require stringent containment and precise manufacturing controls. Specialized facilities offer end-to-end development solutions and robust cross-contamination protections.

  9. Formulation Development Services 10/15/2025

    Quickly address critical formulation issues and optimizing performance. Explore services for small molecules and synthetic peptides across oral, topical, rectal, and parenteral routes.

  10. Accelerating FIH Trials To POC With Speed, Safety, And Certainty 10/15/2025

    Overcome clinical transition challenges with integrated services, including study design, expert regulatory support, robust recruitment, and flexible manufacturing.